Ge
GenEdit
S San Francisco CAFounded 201530 employees
Private CapbiotechPrivateGenetic Medicine
Platform: NP Gene Del
Market Cap
N/A
All Drugs
4
Clinical Trials
9
Failed / Terminated
2
FDA Approved
1
Drug Pipeline (4 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Nidanesiran | GEN-7410 | Approved | 4 | CDK4/6 | RA | ||
| Lisorasimod | GEN-4424 | Phase 2/3 | 2 | EGFR | Fabry | ||
| Voxazanubrutinib | GEN-6349 | Preclinical | 2 | GLP-1R | SCLCFSGS | ||
| GEN-718 | GEN-718 | Phase 1/2 | 1 | TROP-2 | MDS |
Financial Documents
This is a private company — SEC filings are not available.
Catalyst Events (8)